Company Overview

Development Stage

About the Company

[Summary] Dedicated to the research and development of molecularly targeted drug

Founded in 2010, BeiGene is a global innovative company for cancer treatment. As a pioneer in the globalization of innovative drugs, since its inception, we have adhered to the vision of "Developing innovative drugs to benefit humanity" and aspired to be a transformer in the pharmaceutical ecosystem. With an international development philosophy, we lead the transformation of the biomedical industry model and strive to bring accessible and affordable innovative drugs to cancer patients worldwide.

BeiGene is actively committed to making a profound impact on patients and society. To this end, we have taken the lead in establishing an innovative global operating model, building strong differentiated scientific research capabilities, an extensive clinical development layout, scalable autonomous production capacity, and a science-based diversified commercialization strategy. With the growth of our global business, we have built a team of over 11,000 people across six continents. Currently, BeiGene is listed on the NASDAQ in the United States, the Hong Kong Stock Exchange, and the STAR Market of the Shanghai Stock Exchange.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

BeiGene How Fast Is Hiring Growing? (636 open positions)

Manage
Note: How fast is hiring at BeiGene (Beijing) Biologics Co., Ltd. growing? BeiGene2026: 1668 openings (up 148%), 2025: 673 openings (up 346%), 2024: 151 openings (down 51%), 2023: 308 openings (down 13%), 2022: 354 openings (down 65%), 2021: 1024 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

BeiGene Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 143%
  • 2024: Down 71%
  • 2023: Up 9%
  • 2022: Up 32%
BeiGene Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at BeiGene (Beijing) Biologics Co., Ltd. growing? BeiGeneMaster's recruitment over the years: 2025: 51 openings (up 143%), 2024: 21 openings (down 71%), 2023: 72 openings (up 9%), 2022: 66 openings (up 32%), 2021: 50 openings.

BeiGene Doctoral Degree Job Demand Analysis

(More)
+523%
Growth Rate
2026 vs 2025
  • 2025: Up 100%
  • 2024: Down 81%
  • 2023: Down 12%
  • 2022: Up 1000%
BeiGene Doctoral Hiring by Year: 2026 — 115 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at BeiGene (Beijing) Biologics Co., Ltd. growing? BeiGeneDoctorate recruitment over the years: 2026: 137 openings (up 523%), 2025: 22 openings (up 100%), 2024: 11 openings (down 81%), 2023: 58 openings (down 12%), 2022: 66 openings (up 1000%), 2021: 6 openings.

BeiGene R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at BeiGene (Beijing) Biologics Co., Ltd.? Based on an analysis of BeiGene's job postings over the past year, "医疗卫生/美容保健类" demand: 40.8%, "电子/电器/通信技术类": 9.3%, "计算机/网络/技术类": 8%, "生物/制药/化工/环保类": 7.6%, "其他(研发和技术类)": 2.1%, "科研类": 1.8%. For reference only.

BeiGene — What Are the Salaries Like? (1786 records)

Manage
salary range: 2K - 50K, 53.1% of roles pay ¥8-15K
Note: salary statistics are based on 1786 salary records from the past year and depend on the job sample. For reference only.
How is the salary at BeiGene (Beijing) Biologics Co., Ltd.?BeiGene53.1% of positions earn 8-15K, Fresh graduate salary: ¥3.4K。销售类 average salary ¥12.8K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of BeiGene

(More)
Are salaries high at BeiGene (Beijing) Biologics Co., Ltd.? We provide: 医药代表,pr,ma,实习生,ie,市场,te,pe,pa,地区经理,ea,ra,销售,bi,oc,ir,cs,ee,分析,医学联络官. Click to view detailed salary analysis by job.

BeiGene honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 销售类
    53.3% of total 53.3%
  • 医疗卫生/美容保健类
    38.8% of total 38.8%
  • 工厂生产类
    14.3% of total 14.3%
  • 电子/电器/通信技术类
    12.6% of total 12.6%

Education

  • 大专
    36.5% of total 36.5%
  • 本科
    32.6% of total 32.6%
  • 硕士
    12.5% of total 12.5%
  • 不限
    11.2% of total 11.2%

Experience

  • 不限
    44.7% of total 44.7%
  • 5-10年
    19.5% of total 19.5%
  • 3-5年
    17.5% of total 17.5%
  • 1-3年
    16.5% of total 16.5%
View Detailed Analysis

What does BeiGene (Beijing) Biologics Co., Ltd. require? Who is BeiGene hiring? BeiGene recruitment: 销售类占比最多占53.3%,其次是医疗卫生/美容保健类占38.8%. What education can get in at BeiGene? 大专占比最多占36.5%,其次是本科占32.6%. High education required at BeiGene? 硕士占12.5%,博士占7.1%. Work experience required at BeiGene? 不限占比最多占44.7%,其次是5-10年占19.5%. Where are the job locations at BeiGene? 上海占比最多占20.5%,其次是北京占12.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 272,278.7023万(元)
Legal Representative: 吴晓滨
Date Established:
Credit Code: 91110114567400208U
Registered Address: 北京市昌平区中关村生命科学园科学园路30号院1号楼101、201、402、502室

Partners & Suppliers

与宜明昂科就IMM01与替雷利珠单抗联合疗法达成临床合作开发协议,支付预付款和里程碑款 Source
供应商 新药合作开发
采购生物反应器及纯化系统 Source
供应商 制药企业客户
百时益为其提供临床研究服务 Source
供应商 生物技术客户
国药控股分销中心为百济神州创新药分销商 Source
合作客户 生物药
欧璧中国向百济神州供应预灌封注射器,用于其生物药包装。 Source
供应商 医药包装-预灌封注射器

People who follow BeiGene also follow

BeiGene Competitors (Similar Companies)

“Research, development, and production of anti-tumor and surgical medic”
“To develop high-quality biologics that are accessible and affordable f”
“Continuously innovating to bring patients medicines that significantly”
生物科技/生物工程 药物研发 生物制药 抗肿瘤药
“Helping partners successfully develop new drugs, reducing R&D costs an”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
“Global integrated biopharmaceutical enterprise”
制药/药业 抗肿瘤药 肿瘤检测 神经系统疾病药物
“抗衰老及癌症治疗药物研发商”
“Innovative drug R&D”
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Committed to becoming an innovative leader in the field of molecular t”
“改善人们的生活质量”
生物科技/生物工程 医药 分子靶向药物 药物研发
“Large-scale pharmaceutical distribution enterprise”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates